{
    "nctId": "NCT03518034",
    "officialTitle": "Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study",
    "inclusionCriteria": "* Men between 45 and 80 years age\n* Participants with low serum testosterone concentrations (\\< 300 ng/dL) who exhibit at least one sign or symptom of hypogonadism and have evidence of cardiovascular (CV) disease or are at an increased risk for CV disease.\n* Must be MALE\n* Must have minimum age of 45 Years\n* Must have maximum age of 80 Years",
    "exclusionCriteria": "* Participants with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate\n* Participants with prostate specific antigen (PSA) \\> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)\n* Participants who have been treated with testosterone in the past 6 months and for whom testosterone therapy is contraindicated\n* Confirmed testosterone \\< 100 ng/dL\n* Body Mass Index (BMI) \\> 50\n* Hemoglobin A1c (HbA1C) \\> 11%\n* Hematocrit (Hct) \\> 50%\n* Estimated Glomerular Filtration Rate (eGFR) \\< 30 ml/min\n* History of deep vein thrombosis or pulmonary embolism or prostate cancer or heart failure (Class III and IV)."
}